ALX Oncology reports Q3 2026 results, sets December data for ALX2004
The company said it expects ALX2004 Phase 1 safety and early efficacy data in December 2026 and ASPEN-09-Breast topline results in the second half of 2027.
SEC filing
2 stories
The company said it expects ALX2004 Phase 1 safety and early efficacy data in December 2026 and ASPEN-09-Breast topline results in the second half of 2027.
SEC filing
The company entered exchange agreements with Blackstone Annex Master Fund, RA Capital Healthcare Fund, and venBio Global Strategic Fund, set to settle October 15, 2026.
SEC filing